



AI-Pathway Companion Lung Cancer

www.siemens-healthineers.com/ai-pathway



Lung cancer vision Siemens Healthineers




Along the patient's disease pathway

Improving survival rates and lung cancer patients' lives through early detection and personalized, smart therapy¹.

¹ AI-Pathway Companion Lung Cancer is not commercially available in all countries.


AI-Pathway companion focuses on domain expertise in the field of oncology

Multi-disease approach along the entire patient journey




The products/features (mentioned herein) of AI-Pathway Companion are not commercially available in all countries. Their future availability cannot be guaranteed. AI-Pathway Companion Lung Cancer and AI-Pathway Companion Breast Cancer are under development and not commercially available. Their future availability cannot be ensured.

Diagnosing and treating Non-Small Cell Lung Cancer



AI-Pathway Companion Lung Cancer¹ workflow in NSCLC



¹ AI-Pathway Companion Lung Cancer is under development and not commercially available. The future availability cannot be ensured.


A comprehensive multidisciplinary team (MDT) program for lung cancer yields improved patient outcomes

1. A significant aspect of cancer care is the challenge of preparing and conducting MDTs.
2. Data is distributed across multiple systems and cannot be easily aggregated or integrated.
3. The goal is to better capture, organize, and present essential information and to enable advanced analytics and workflow optimizations.
4. This can be achieved via digitalization of workflow and standardization of case reviews in a single dashboard accessible by all MDT members.



AI-Pathway Companion¹ facilitates standardized tumor board preparation and efficient collaboration across specialties


Improving efficiency of MDT discussions in Lung Cancer: Adequate patient planning before MDT meeting



“During lung MDT discussion, it frequently becomes apparent that a key diagnostic report or other crucial information is not yet available. These patients have to be discussed again in the next meeting. This wastes time and effort for all physicians involved in the MDT. A digital assistant, which ensures that the right set of information is available, would substantially increase efficiency”

Prof. Mathias Prokop², MD PhD
Head of the department Radiology, Nuclear Medicine and Anatomy

Radboudumc
university medical center




AI-Pathway Companion Lung Cancer is under development and not commercially available. The future availability cannot be ensured.

1 Based on 901 lung cancer patients scheduled for MDTs in Jan – Dec 2019

2 Prof. Mathias Prokop is employed by an institution that receives financial support from Siemens Healthineers for collaborations.


AI-Pathway Companion improves transparency of clinical guideline complexity

Complexity of clinical guidelines




AI-PC


AI-PC provides transparency on recommended guideline treatment options and alternatives




AI-Pathway Companion supports key challenges in diagnosis and treatment of NSCLC by ...



... providing the ability to have quick snapshot overview



... collecting relevant imaging and pathology findings in one place¹



... mapping the patients to clinical guidelines such as NCCN and ESMO²

The products/features (mentioned herein) of AI-Pathway Companion are not commercially available in all countries. Their future availability cannot be guaranteed.

AI-Pathway Companion Lung Cancer is under development and not commercially available. The future availability cannot be ensured

1 This function is supported by AI-Pathway Companion Connector.

2 Prerequisite: "All data is available as required per guideline." Feature dependent on quality of input data.